Optimizing Oncology Prior Authorization with Change Healthcare Clearinghouse

Navigating the complexities of oncology prior authorization demands robust infrastructure. Klivira integrates with Change Healthcare Clearinghouse to streamline medical benefit PA submissions for high-cost cancer therapies.

For revenue cycle directors and prior authorization coordinators in oncology, managing the high volume and complexity of PAs is a significant challenge. Delays impact patient care and financial health. Leveraging a national clearinghouse like Change Healthcare for efficient data exchange is critical, particularly for the intricate requirements of cancer care.

The Unique Prior Authorization Landscape in Oncology

Oncology presents some of the most intricate prior authorization requirements in healthcare. High-cost biologics, frequent regimen changes, and advanced imaging for staging and surveillance contribute to a high PA volume per patient. This necessitates a PA workflow that can adapt to the urgency of cancer treatment and the continuous evolution of care plans.

Key Oncology PA Triggers and Documentation Needs

**J-code chemotherapy and biologic infusions:** Each cycle and regimen change for HCPCS J-codes triggers a PA event.
**Advanced imaging:** PET/CT, advanced MRI, and tumor-specific molecular imaging for staging and surveillance require PA.
**Radiation oncology procedures:** IMRT, IGRT, SBRT, brachytherapy, and proton-beam therapy often require treatment plan approval and per-fraction billing PA.
**Genetic and molecular testing:** NGS panels and single-gene tests for treatment selection and risk stratification.
**NCCN Clinical Practice Guidelines:** The dominant medical-necessity framework, requiring specific pathology, molecular markers (e.g., ER/PR/HER2, EGFR/ALK/PD-L1), performance status (ECOG/Karnofsky), and prior treatment response documentation.

Leveraging Change Healthcare Clearinghouse for Oncology PA Submissions

Change Healthcare, an Optum-owned national clearinghouse, is a critical conduit for HIPAA X12 transactions, including eligibility (270/271) and prior authorization (278). For oncology, efficient and accurate X12 278 submissions are paramount for medical benefit drugs and services. This integration ensures that the detailed clinical documentation required for oncology PAs is transmitted securely and correctly, minimizing manual intervention and accelerating payer review cycles.

Addressing Common Oncology PA Denials via Optimized Clearinghouse Workflows

Oncology PA denials frequently stem from issues like off-label use without NCCN Compendium support, step therapy requirements, documentation gaps (e.g., missing molecular marker results), or site-of-service mismatches. A robust integration with Change Healthcare Clearinghouse facilitates the submission of comprehensive data upfront, reducing the likelihood of these common denials and enabling faster appeals when necessary, particularly for NCD/LCD non-coverage for Medicare Advantage plans.

Klivira's Solution for Oncology PA and Change Healthcare Integration

Klivira's prior authorization automation platform is engineered to address the unique demands of oncology, seamlessly integrating with EMRs and clearinghouses like Change Healthcare. Our system incorporates NCCN-compendium-aware policy logic to guide documentation, supports regimen-level PA submissions, and intelligently routes medical-benefit PAs via X12 278. This ensures that the high volume of concurrent PA events per oncology patient, from initial treatment to supportive care and surveillance, is managed efficiently and accurately through established clearinghouse channels.

Key Klivira Capabilities for Oncology & Clearinghouse Workflow

**NCCN-compendium-aware logic:** Guides required documentation per regimen and tumor type at order entry.
**Regimen-level PA workflow:** Bundles related components for single submissions where supported, or manages separate submissions.
**Medical-vs-pharmacy benefit routing:** Handles the split between medical benefit (via X12 278 through clearinghouses like Change Healthcare) and pharmacy benefit (via ePA partners).
**Concurrent PA tracking:** Manages dozens of PA events per patient across diagnosis, treatment, and surveillance.
**Peer-to-peer scheduling integration:** Streamlines the coordination for clinical-necessity denial reviews with oncologists and payers.

Frequently asked questions

How does Klivira integrate with Change Healthcare for oncology prior authorizations?

Klivira integrates with EMRs to extract clinical data and then leverages Change Healthcare Clearinghouse for the electronic submission of medical benefit prior authorizations via HIPAA X12 278 transactions. This automation ensures accurate and efficient data exchange, reducing manual effort and accelerating the PA process for oncology treatments and services.

What specific oncology PA challenges does clearinghouse integration address?

Clearinghouse integration primarily addresses the efficient and standardized electronic submission of medical benefit PAs for high-cost oncology drugs and services. It helps ensure that comprehensive clinical documentation, guided by NCCN guidelines, is accurately transmitted, reducing data entry errors and facilitating faster payer review cycles for urgent oncology cases.

Does Klivira handle both medical and pharmacy benefit PAs through Change Healthcare?

Klivira handles both medical and pharmacy benefit PAs, but their routing differs. Medical benefit PAs, typically for provider-administered infusions (J-codes), are routed via X12 278 through clearinghouses like Change Healthcare. Pharmacy benefit PAs, for oral oncolytics, are routed through the payer's PBM and ePA partners, not typically through a medical clearinghouse.

How does the urgency of oncology treatment impact PA workflows with a clearinghouse?

The urgency in oncology demands rapid PA turnaround. Efficient clearinghouse integration, combined with Klivira's automation, minimizes the time from treatment order to PA submission and approval. This reduces delays that could impact patient outcomes, particularly for aggressive cancers requiring immediate intervention.

What role do NCCN guidelines play in oncology PA submissions via a clearinghouse?

NCCN Clinical Practice Guidelines are the primary medical necessity framework for oncology PAs. Klivira's platform is designed with NCCN-compendium-aware logic, ensuring that all required documentation aligned with these guidelines is captured and included in the X12 278 submission via Change Healthcare, supporting medical necessity and reducing denials.